Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P41223
UPID:
BUD31_HUMAN
Alternative names:
Protein EDG-2; Protein G10 homolog
Alternative UPACC:
P41223; A4D274; B7Z4S9; D6W5S6; Q6IB53; Q9UDV1
Background:
Protein BUD31 homolog, also known as Protein EDG-2 and Protein G10 homolog, plays a crucial role in the pre-mRNA splicing process. This protein is not only pivotal in RNA splicing but also acts as a regulator of AR transcriptional activity, potentially enhancing AR transcriptional functions.
Therapeutic significance:
Understanding the role of Protein BUD31 homolog could open doors to potential therapeutic strategies. Its involvement in pre-mRNA splicing and regulation of AR transcriptional activity highlights its importance in cellular processes and its potential as a target for therapeutic intervention.